AMP-activated protein kinase, AMPK · PROTEIN COMPLEX GROUP · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14AMP-activated protein kinase, AMPK shows late clinical disease relevance led by cardiovascular disease. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P54646. Start with cardiovascular disease, then reuse UniProt P54646 as the stable protein anchor across project notes and exports.
Start with cardiovascular disease, then reuse UniProt P54646 as the stable protein anchor across project notes and exports.
AMP-activated protein kinase, AMPK shows late clinical disease relevance led by cardiovascular disease. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with cardiovascular disease because it currently carries late clinical support. Linked drugs include ACADESINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxy5'-AMP-activated protein kinase catalytic subunit alpha-2
Review this target as AMP-activated protein kinase, AMPK, mapped to UniProt P54646. ChEMBL maps the protein component as 5'-AMP-activated protein kinase catalytic subunit alpha-2. Sequence length is 552 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats AMP-activated protein kinase, AMPK as ChEMBL target CHEMBL2096907, mapped to UniProt P54646. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether AMP-activated protein kinase, AMPK is the right protein anchor across sources, using UniProt P54646 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cardiovascular disease is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | AMP-activated protein kinase, AMPK |
| Target Type | PROTEIN COMPLEX GROUP |
| Organism | Homo sapiens |
| UniProt | P54646 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | 5'-AMP-activated protein kinase catalytic subunit alpha-2 |
| UniProt Accession | P54646 |
| Component Type | Protein |
| Sequence Length | 552 aa |
5'-AMP-activated protein kinase catalytic subunit alpha-2
Review this target as AMP-activated protein kinase, AMPK, mapped to UniProt P54646. ChEMBL maps the protein component as 5'-AMP-activated protein kinase catalytic subunit alpha-2. Sequence length is 552 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
AMP-activated protein kinase, AMPK shows late clinical disease relevance led by cardiovascular disease. 1 more disease program remain visible in the same review block.
Start review with cardiovascular disease because it currently carries late clinical support. Linked drugs include ACADESINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3986249 | 9.3 | EC50 | 0.5 | Preclinical |
| CHEMBL4167177 | 9.0 | EC50 | 1.0 | Preclinical |
| CHEMBL5179319 | 9.0 | EC50 | 1.0 | Preclinical |
| CHEMBL5181529 | 9.0 | EC50 | 1.0 | Preclinical |
| CHEMBL5183579 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL5183763 | 9.0 | EC50 | 1.0 | Preclinical |
| CHEMBL3975011 | 8.77 | EC50 | 1.7 | Preclinical |
| CHEMBL3923669 | 8.74 | EC50 | 1.8 | Preclinical |
| CHEMBL4111692 | 8.7 | EC50 | 2.0 | Preclinical |
| CHEMBL5180431 | 8.7 | EC50 | 2.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 110 | 73 | 7.1 |
| protein complex format | 94 | 219 | 7.1 |
| assay format | 22 | 7 | 7.1 |
| tissue-based format | 2 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 23 | 4.8 |